Apollomics, Inc. (APLM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Apollomics, Inc. (APLM) closed at USD 21.77 on 2026-10-14, a change of +4.4 % over the past year, with a market capitalization of USD 61.21M.

Apollomics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Apollomics, Inc. key figures

Previous close

USD 21.77 (2026-10-14)

1-year change

+4.4 %

Market cap

USD 61.21M

Enterprise value

USD 43.48M

P/E ratio (trailing)

-2.77

P/E ratio (forward)

-32.31

EPS (trailing)

-7.57

EPS (forward)

-0.65

PEG ratio

n/a

Price to book

-14.14

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.54

Employees

14

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Apollomics, Inc.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Apollomics, Inc. and compare it with other stocks.